Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | STK11 inact mut |
Therapy | Everolimus |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
STK11 inact mut | lung adenocarcinoma | predicted - sensitive | Everolimus | Case Reports/Case Series | Actionable | In a Phase II trial, Afinitor (everolimus) treatment resulted in a complete response lasting more than 10 months in a heavily pre-treated patient with lung adenocarcinoma harboring 2 in cis non-coding STK11 mutations (STK11 c.375-2del and c.375-G>C), (PMID: 34422335; NCT02352844). | 34422335 |
PubMed Id | Reference Title | Details |
---|---|---|
(34422335) | A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. | Full reference... |